Evidence map›Paper›PMID 40182188›Full record

ArticleACG case reports journal2025

Terlipressin-Associated Complete Heart Block.

Jiunn Song, Tristan Alfie, E Kevin Heist, Raymond T Chung

Abstract readCase Reports
In one paragraph

Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiunn SongDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.ORCID https://orcid.org/0000-0002-4206-3291
Tristan AlfieInternal Medicine Residency Program, Massachusetts General Hospital, Boston, MA.
E Kevin HeistDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Raymond T ChungDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Terlipressin has been recently approved in the United States to treat hepatorenal syndrome, a feared complication of both acute and chronic liver diseases. Side effects of the medication have been studied through clinical trials and the precedent use in Europe, as well as extrapolation from its analog vasopressin. As its use is becoming more prevalent, unforeseen complications have arisen. We report a case of complete heart block associated with terlipressin use in presumed hepatorenal syndrome in acute liver injury.

Indexed as

acute liver injurycomplete heart blockhepatorenal syndromeTerlipressin

Identifiers

PMID40182188
PMCPMC11968014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.